Latest Old Line Bancshares (OLBK) Headlines Balanced

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Old Line Bancshares (OLBK) Headlines

Balanced Risk-Reward for PNC Financial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 4:40PM CST
On Feb 18, 2014, we issued an updated research report on The PNC Financial Services Group. Inc.

Old Line Bancshares Hits New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 2:31PM CST
Shares of Old Line Bancshares Inc. crafted a new 52-week high, touching $17.64 in the beginning of the trading session on Feb 7

Old Line Bancshares, Inc. Reports Strong Organic Loan Growth of 22.65% for the Year and Increased Earnings of 157.9% for the Fourth Quarter Ended December 31, 2013
GlobeNewswire - Mon Jan 27, 5:06PM CST
Old Line Bancshares, Inc. (Nasdaq:OLBK), the parent company of Old Line Bank, reported net income available to common stockholders of $7.8 million for the year ended December 31, 2013. Net income increased $308,000 or 4.10% for the year, compared to net income of $7.5 million for the year ended December 31, 2012. Earnings were $0.87 and $0.86 per basic and diluted common share, respectively, for the year ended December 31, 2013 and $1.10 and $1.09, respectively, per basic and diluted common share in 2012. The increase in net income is primarily the result of a $6.9 million increase in net interest income and a $5.2 million increase in non-interest income, offsetting an increase of $10.9 million in non-interest expense. Non-interest income increased as a result of $3.4 million in gains on the sale of approximately $22.6 million of loans acquired in the Bank's two acquisitions.

Can Old Line Bancshares (OLBK) Continue to Rise? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 22, 6:49AM CST
Can Old Line Bancshares (OLBK) Continue to Rise?

Nasdaq stocks posting largest volume increases
AP - Thu Jan 16, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:

Why You Shouldn't Bet Against Old Line Bancshares (OLBK) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 26, 6:42AM CST
Old Line Bancshares is seeing solid earnings estimate revision activity and also enjoys great company from a Zacks Industry Rank perspective

Earnings Estimates Moving Higher for Old Line Bancshares Inc (OLBK): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 18, 6:25AM CST
Teaser Message: Old Line Bancshares could be an interesting play for investors, as it is seeing solid activity on the earnings estimate revision front.

Old Line Bancshares Hit 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 04, 11:12AM CST
Shares of Old Line Bancshares hit its 52-week high of $38.38 on Dec 3 on the back of solid third-quarter results and its efforts to strengthen its balance sheet.

Old Line Bancshares Adds New Board Member
GlobeNewswire - Thu Nov 21, 1:10PM CST
Old Line Bancshares, Inc. (Nasdaq:OLBK), the parent company of Old Line Bank, today announced that Thomas H. Graham, Vice President People Strategy and Human Resources for Pepco Holdings, Inc. (PHI) was appointed to its Board of Directors.

Old Line Bancshares, Inc. Disposes of Credit Impaired Loans Purchased in Its Past Merger Transactions
GlobeNewswire - Tue Nov 19, 11:30AM CST
Old Line Bancshares, Inc. (Nasdaq:OLBK), the parent company of Old Line Bank, announced that since September 30, 2013, it has disposed of approximately $22.6 million of loans acquired in the April 2011 merger with Maryland Bankcorp, Inc., the May 2013 merger with WSB Holdings, Inc. and the repurchase, from another bank, of a participation on one of the WSB Holdings, Inc. credit impaired loans. This disposal was accomplished through brokered sales transactions. The disposals included approximately $12.0 million of loans that were over 90 days past due.

Old Line Bancshares, Inc. Announces Approval of Class Action Settlement, no Award of Attorneys Fees to Class Counsel
GlobeNewswire - Wed Nov 13, 2:45PM CST
Old Line Bancshares, Inc. (Nasdaq:OLBK), the parent company of Old Line Bank, today announced that on November 12, 2013, the Circuit Court for Prince George's County, Maryland approved its previously-disclosed Stipulation of Settlement to resolve all claims asserted on behalf of a putative class of WSB Holdings, Inc. stockholders in connection with Old Line Bancshares, Inc.'s acquisition of WSB Holdings, Inc., which was completed on May 10, 2013. As previously disclosed, the settlement required Old Line Bancshares, Inc. and WSB Holdings, Inc. to make certain additional disclosures related to the merger, which disclosures were included in the joint proxy statement/prospectus of Old Line Bancshares, Inc. and WSB Holdings, Inc. previously sent to their respective stockholders, and does not include any payment to class members.

Old Line Bank Strengthens Management Team and Adds Marketing & Mortgage Talent
GlobeNewswire - Fri Nov 01, 10:45AM CDT
Old Line Bancshares, Inc. (Nasdaq:OLBK), the parent company of Old Line Bank, announced the addition of two new senior level officers to the Bank's management team to support its Marketing and Mortgage Banking Divisions.

Old Line Bancshares, Inc. Reports Earnings Increase of 8.88% for the Three Months Ended September 30, 2013
GlobeNewswire - Tue Oct 29, 2:50PM CDT
Old Line Bancshares, Inc. (Nasdaq:OLBK), the parent company of Old Line Bank, reported net income available to common stockholders of $2.2 million for the three month period ended September 30, 2013. Net income increased $180,000 or 8.88% for the three month period, compared to net income of $2.0 million for the three months ended September 30, 2012. Earnings were $0.22 per basic and diluted common share for the three months ended September 30, 2013 and $0.30 and $0.29, respectively, per basic and diluted common share for the same period in 2012. The increase in net income is primarily the result of a $2.9 million increase in total interest income and a $759,000 increase in non-interest income, offsetting an increase of $3.2 million in non-interest expense. Non-interest income increased as a result of gains on sale of residential loans sold in the secondary market and an increase in other fees and commissions.

Old Line Bancshares, Inc. Announces Completion of Private Placement
GlobeNewswire - Mon Sep 16, 8:30AM CDT
Old Line Bancshares, Inc. (Nasdaq:OLBK), the parent company of Old Line Bank, today announced that it has completed the sale of 925,079 shares of its common stock at a price of $13.00 per share to accredited investors. Old Line Bancshares, Inc. has received proceeds of approximately $12.0 million after expenses as a result of the private placement. Old Line Bancshares, Inc. intends to use the proceeds of the offering for additional working capital and other general corporate purposes.

Faruqi & Faruqi, LLP Launches An Investigation Against Old Line Bancshares, Inc. (OLBK) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
Business Wire - Tue Jul 30, 6:00PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Old Line Bancshares, Inc. ("Old Line" or the "Company") (NasdaqCM: OLBK) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for an amendment of the Company's 2010 Equity Incentive Plan.

Old Line Bancshares Inc. (OLBK) Stock Research Links

OLBK Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 190

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 144

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 59

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 80

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 299

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 242

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 96

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 104

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading

Top 5 Most Recently Viewed Articles

Macao's 25-Year Journey: Celebrating Growth and Prosperity

Updated Category News Views 161

Macao's Remarkable Development Over 25 Years In a vibrant celebration of progress, Macao recently marked the significant milestone of its 25th anniversary since its return to the motherland. A special publication by an English-language newspaper highlighted various achievements that the region has made during this transformative period. Economic Growth and Transformation...

Continue Reading
Opportunity to Address Losses: Join Tempus AI Class Action

Updated Category News Views 128

Investors Encouraged to Participate in Tempus AI Class Action The law firm Robbins Geller Rudman & Dowd LLP is actively reaching out to investors of Tempus AI, Inc. (NASDAQ: TEM) who have experienced notable financial losses. They have announced an opportunity for eligible investors to take the lead in an associated class action lawsuit. This potential action stems from...

Continue Reading
Muncy Columbia Financial Corporation's Strong Q4 2024 Earnings

Updated Category News Views 99

Muncy Columbia Financial Corporation's Financial Outlook Muncy Columbia Financial Corporation (“Corporation”) (OTCQX: CCFN), after releasing its unaudited consolidated financial statements for the fourth quarter of 2024, has demonstrated significant improvement over the previous year. Fourth Quarter 2024 Financial Highlights For the quarter ending December 31, 2024,...

Continue Reading
Caris Life Sciences Expands Cancer Research Alliance

Updated Category News Views 119

Caris Life Sciences Expands Cancer Research Alliance Caris Life Sciences® (NASDAQ: CAI), a forefront player in precision medicine and next-generation AI TechBio, is excited to share the arrival of Providence Swedish Cancer Institute into the esteemed Caris Precision Oncology Alliance (Caris POA). This addition enhances their collective mission to revolutionize cancer...

Continue Reading
Zumiez Inc. Gears Up for First Quarter 2025 Financial Report

Updated Category News Views 263

Upcoming Financial Report for Zumiez Inc. Zumiez Inc. (NASDAQ: ZUMZ) has recently made an exciting announcement regarding its financial performance. The company is set to release its first quarter results for fiscal 2025 on June 5, after the stock market closes. This pivotal moment is eagerly anticipated by investors and stakeholders alike, as it will provide valuable...

Continue Reading